As part of an ongoing series, we are taking a look at how evidence can help us identify the health and cost impact of treatments on patients, while also highlighting areas of unmet patient needs. Earlier posts can be found here and here.
Rich Fante, President, AstraZeneca U.S. and CEO North America, has been elected chairman of the National Pharmaceutical Council (NPC) – reflecting AstraZeneca’s commitment to comparative effectiveness research and other evidence-based research with the potential to benefit patient care. This includes our emerging emphasis on real-world evidence as detailed here.
Established in 1953 and supported by the nation’s major research-based pharmaceutical companies, NPC is a policy research organization that sponsors and conducts scientific analyses of the appropriate use of biopharmaceuticals and the clinical and economic value of innovation. The organization’s strategic focus is on evidence-based medicine for health care decision-making, to ensure that patients have access to high-quality care.
“NPC has an important and unique role to play in supporting the development and application of comparative effectiveness research and other data important to improving health outcomes,” Fante said. “By engaging with providers, payers, policymakers and other stakeholders, NPC will be able to meaningfully contribute to shaping the health care environment.”
AstraZeneca believes comparative effectiveness research must be used to:
- Strengthen and improve quality of care – and not solely be used as a means to contain costs.
- Encourage the development of innovative health care – and not be used as the sole rationale for product approval, coverage, pricing or reimbursement decisions.
- Employ rigorous and transparent research methodologies.
As policymakers continue to use comparative effectiveness research, we encourage them to keep clinical effectiveness at the forefront of their efforts – recognizing the individual nature of patient responses to therapy.
Please join us here and on Twitter for an ongoing discussion about comparative effectiveness, real-world evidence (#RWEv) and other areas of evidence-based medicine.